Abstract:TPS349 Background: Androgen Deprivation Therapy (ADT) with external beam radiation therapy (EBRT) is a standard of care for patients (pts) with unfavorable intermediate-risk prostate cancer (Pca). However, ADT generates side effects with 30% decrease of quality of life (QoL). Enzalutamide (E) and Darolutamide (D) combined with ADT offer an overall survival benefit in advanced Pca. Without ADT, E avoid most of the deleterious effects of ADT. In a population of pts with intermediate risk Pca, 92% achieved PSA values < 0.1 ng/ml at the end of a treatment with EBRT and E alone. 1 In pre-clinical models treated with D alone, testosterone (T) level remained normal. 2 Such side effects related to T loss and to peripheral aromatization of T might be decreased with D alone. We assume that a combination of D given 6 months with EBRT in the treatment of unfavorable intermediate risk Pca is efficient and safe, without consequences on QoL. Methods: DARIUS is a national, multi-center, non-comparative randomized phase II prospective study (NCT05346848). The primary objective is to assess antitumor activity of D given 6 months with EBRT in pts with unfavorable intermediate risk Pca, using a biological response defined as PSA ≤0.1ng/ml, 6 months after randomization. D 6 months + EBRT and ADT 6 months + EBRT are offered in experimental and standard arm respectively. Randomization is 2:1. Regarding the experimental arm, given that E used alone achieved a 49% 6-month biological response rate in a hormone-sensible Pca pts, 3 the association D + EBRT will be considered useful if it can increase this rate to at least 70%. Using a single-stage design, standard response rate (P0) is 50% and alternative hypothesis P1 is 70% (one-sided 5% type I error rate, 80% power). Following one-stage A’Hern design, 37 and 19 pts are required in the experimental and standard arm, respectively. Adding 10% of non-eligible/assessable pts, the total number is 62. Enrollment have already begun and 5 pts have been enrolled. Inclusion criteria are: PS ECOG ≤ 2; histological diagnosis of Pca, without metastasis (on Pelvic MRI AND thoraco-abdomino-pelvic contrast-enhanced CT-Scan AND Bone Scintigraphy); with unfavorable intermediate risk Pca diagnosis (NCCN Guidelines): 1- either Gleason = 7 (4+3) OR, 2- ≥ 50% of the core of biopsies positive for adenocarcinoma OR, 3- two or three of the following criteria (PSA value between 10-20 ng/ml, Gleason 7 (3+4) or 6, T2b (clinical or radiological)). Pts with T3a extension on MRI can be included if Gleason score is 6 and PSA < 20. Secondary objectives are biochemical Progression Free Survival, MFS, DFS, Pca-specific survival, Time to T recovery, safety, QoL and bone mineral density. Predictive factors will be investigated using Radiomics and DECIPHER. 1. Lara Front Oncol 2022. 2. Molainen Sci Rep 2015. 3. Tombal Lancet Oncol 2014. Clinical trial information: NCT05346848 .

EORTC 2238 "De-Escalate": a pragmatic trial to revisit intermittent androgen deprivation therapy in the era of new androgen receptor pathway inhibitors

EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-naïve prostate cancer in the era of new AR pathway inhibitors.

A Phase 1b Adaptive Androgen Deprivation Therapy Trial in Metastatic Castration Sensitive Prostate Cancer

Is There an Opportunity to De-Escalate Treatments in Selected Patients with Metastatic Hormone-Sensitive Prostate Cancer?

A phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naive prostate cancer: ARAMON study.

Real-world (RW) survival and outcomes with androgen receptor pathway inhibitor (ARPI) –doublet therapy in patients (pts) with de novo metastatic castration-sensitive prostate cancer (mCSPC).

A randomized, non-comparative, phase II multicentric trial on short-term darolutamide (ODM-201) concomitant to radiation therapy for patients with unfavorable intermediate-risk prostate cancer: DARIUS (AFU-GETUG P15).

Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial

Real-world treatment patterns among French patients with metastatic castration-resistant prostate cancer under abiraterone or enzalutamide.

GUIDE: A randomized non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (ANZUP 1903).

A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer

DynAMo: A dynamic allocation modular sequential trial of approved and promising therapies in men with metastatic CRPC.

Intra-individual Dose Escalation of Abiraterone According to Its Plasma Exposure in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer: Results of the OPTIMABI Trial

A phase IIa study of sequential ("first strike, second strike") therapies, modeled on evolutionary dynamics of anthropocene extinctions, for high-risk metastatic castration-sensitive prostate cancer.

Deutenzalutamide, an oral deuterated androgen receptor inhibitor, vs placebo for patients with mCRPC who have experienced treatment failure with abiraterone and docetaxel: Results of the HC-1119-04 phase 3 trial.

Apalutamide (APA) plus intermittent versus continuous androgen-deprivation therapy (ADT) in participants (pts) with metastatic castration-sensitive prostate cancer (mCSPC): LIBERTAS phase 3 study design.

A 16-year clinical experience with intermittent androgen deprivation for prostate cancer: oncological results

Intensification of ADT with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation: Initial results from RTOG 3506 (STEEL).

Optimizing Treatment in Intermediate-Risk Prostate Cancer: Secondary Analysis of a Randomized Phase 3 Trial

Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial

Transdermal oestradiol and exercise in androgen deprivation therapy (ESTRACISE): protocol